RE: RE: Transcript: PharmaTelevision interview witWow, great interview! That's the best reply you can come up with Arty?, "interesting but nothing new"?
Seems to me a public satement that Urocidin phase III only had "one adverse effect in 129 patients" is new, as well as being incredible. In fact that entire interview is incredible! Much better public exposure information coming out of that interview then I expected.
If you want more BNC at anything close to this price you better be quick and nimble in the morning. (You must already have your premarket order in Art, is that why you are feining the hohum response? We could have a few thousand new investors fianally discovering what is going on with this little giant of a company over the next few days and taking up some healthy positions. Bring on the phase III release showing decent efficacy along, with this safety profile, and we are truly the stock of the decade in the making.